PT Bayer Indonesia is to continue to invest and support the development of the pharmaceutical industry in Indonesia by inaugurating a new warehouse at its state-of-the-art healthcare manufacturing plant in Cimanggis, Depok, West Java.
The current expansion is part of an ongoing €8.1m investment that aims to increase the overall manufacturing capability of the facility, enabling it to export global healthcare brand products to more than 20 countries this year and many more in the future.
Saleh Husin, the Indonesian Minister of Industry, said: ‘Foreign investment has become a key stimulant for industrial growth and labour absorption. Indonesia’s economic growth needs to be sustained, especially in the non-mineral and gas sectors, which include pharmaceuticals. On behalf of the government of Indonesia, the Ministry of Industry extends its sincere appreciation to Bayer for their commitment and for continuing with their investment in the production facility in Cimanggis.'
Bayer’s Cimanggis facility uses both effervescent and non-effervescent production technologies to manufacture over-the-counter pharmaceutical and multivitamin products. As part of its ongoing investment, another production line for pharmaceutical effervescent products is also being constructed. In the near future, Bayer plans to increase its production capacity at the Cimanggis plant.
President Director of PT Bayer Indonesia, Ashraf Al-Ouf, said: ‘In line with our mission statement, we are committed to help people around the world, including Indonesia, to achieve a better quality of life. We see Indonesia both as an important market and a strong location to produce global brands for export to many countries around the world.
‘We are very proud of our investment and operation here at Cimanggis. I am also very glad to hear the Minister of Industry’s assurance that the government of Indonesia will continue their reform and strengthen collaboration to provide a better environment to invest in the country,’ he added.